Stockholm, Sweden, June 3, 2024
AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board.
Michael has had a long and successful career in the pharmaceutical industry, leading large value business development transactions across multiple therapeutic areas and products. Michael spent more than two decades at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and
M&A. Since his retirement in 2018, Michael has served on the boards of several public biotechnology companies. He holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
Michael Grissinger commented: “AnaCardio, with its promising novel concept to treat heart failure, is an exciting Swedish company with potential to address a significant unmet patient need. I am looking forward to being a part of the journey forward.”
Mark Quick, board member, Partner at Flerie and outgoing chairman commented: “We are delighted to welcome Michael to the board as the new chairman. With his long tenure and track record in business development and M&A at leading pharma companies, he brings the exact credentials required to continue building the AnaCardio success story.”
About AnaCardio
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule, which is being developed as a contractile agent in heart failure patients.
You can find more information about AnaCardio at www.anacardio.com.
For further information, please contact
Patrik Strömberg, CEO
Telephone: +46 704 156 159
E-mail: Patrik.stromberg@anacardio.com
